Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
NCNA
$2.2401
$
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Next Earnings
2026-02-25
Beta
1.689
Average Volume
Market Cap
Last Dividend
CIK
0001709626
ISIN
US67022C3043
CUSIP
67022C304
CEO
Hugh Stephen Griffith
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
20
IPO Date
2017-09-28
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| NuCana Appoints Theresa Bruce as Chief Operating Officer | EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. | GlobeNewsWire | 2026-01-06 08:00:00 |
| NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma | Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings | GlobeNewsWire | 2025-12-10 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-01-06 | 2026-01-06 | View Filing |
| 6-K | 2025-12-17 | 2025-12-17 | View Filing |
| 6-K | 2025-12-10 | 2025-12-10 | View Filing |
| 6-K | 2025-11-13 | 2025-11-13 | View Filing |
| 6-K | 2025-11-05 | 2025-11-05 | View Filing |
| 6-K | 2025-10-14 | 2025-10-14 | View Filing |
| 6-K | 2025-09-05 | 2025-09-05 | View Filing |
| 6-K | 2025-09-03 | 2025-09-03 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| 6-K | 2025-07-21 | 2025-07-21 | View Filing |
| F-6 POS | 2025-07-16 | 2025-07-16 | View Filing |
| 6-K | 2025-07-11 | 2025-07-11 | View Filing |
| 6-K | 2025-07-09 | 2025-07-09 | View Filing |
| 6-K | 2025-06-30 | 2025-06-30 | View Filing |
| 424B5 | 2025-06-27 | 2025-06-27 | View Filing |
| 6-K | 2025-06-27 | 2025-06-27 | View Filing |
| EFFECT | 2025-06-25 | 2025-06-25 | View Filing |
| 6-K | 2025-06-20 | 2025-06-20 | View Filing |
| F-3/A | 2025-06-18 | 2025-06-18 | View Filing |
| 6-K | 2025-06-18 | 2025-06-18 | View Filing |
| 6-K | 2025-06-05 | 2025-06-05 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 424B4 | 2025-05-07 | 2025-05-07 | View Filing |
| EFFECT | 2025-05-06 | 2025-05-06 | View Filing |
| EFFECT | 2025-05-06 | 2025-05-06 | View Filing |
| F-1/A | 2025-05-02 | 2025-05-01 | View Filing |
| F-1/A | 2025-04-29 | 2025-04-29 | View Filing |
| F-6 | 2025-04-24 | 2025-04-24 | View Filing |
| F-1 | 2025-04-24 | 2025-04-24 | View Filing |
| 6-K | 2025-04-23 | 2025-04-23 | View Filing |
| SC 13D/A | 2025-04-18 | 2025-04-18 | View Filing |
| 20-F | 2025-03-20 | 2025-03-20 | View Filing |
| 6-K | 2025-03-20 | 2025-03-20 | View Filing |
| 6-K | 2025-03-18 | 2025-03-18 | View Filing |
| SC 13D/A | 2025-02-25 | 2025-02-25 | View Filing |
| SC 13D/A | 2025-02-14 | 2025-02-14 | View Filing |
| 6-K | 2025-02-10 | 2025-02-10 | View Filing |
| 6-K | 2024-11-25 | 2024-11-25 | View Filing |
| 6-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-10-04 | 2024-10-04 | View Filing |
| 424B5 | 2024-10-01 | 2024-10-01 | View Filing |
| 6-K | 2024-10-01 | 2024-09-30 | View Filing |
| 6-K | 2024-09-26 | 2024-09-26 | View Filing |
| 6-K | 2024-09-16 | 2024-09-16 | View Filing |
| 6-K | 2024-08-29 | 2024-08-29 | View Filing |
| F-3 | 2024-08-15 | 2024-08-15 | View Filing |
| 6-K | 2024-08-15 | 2024-08-15 | View Filing |
| 6-K | 2024-06-18 | 2024-06-18 | View Filing |
| 6-K | 2024-05-16 | 2024-05-16 | View Filing |
| 6-K | 2024-05-13 | 2024-05-13 | View Filing |
| 6-K | 2024-05-01 | 2024-05-01 | View Filing |
| 6-K | 2024-04-16 | 2024-04-16 | View Filing |
| 6-K | 2024-04-09 | 2024-04-09 | View Filing |
| F-6 POS | 2024-03-27 | 2024-03-27 | View Filing |
| 424B5 | 2024-03-27 | 2024-03-27 | View Filing |
| 6-K | 2024-03-27 | 2024-03-27 | View Filing |
| 20-F | 2024-03-20 | 2024-03-20 | View Filing |
| 6-K | 2024-03-20 | 2024-03-20 | View Filing |
| SC 13D/A | 2024-02-27 | 2024-02-27 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 5.15% | 1.49 | 23 | 0.97 | 1.19 | 11.4 |
| Larry Williams PercentR Strategy | 4.57% | 1.97 | 19 | 1.02 | 17.28 | 10.82 |
| ADX | 4.33% | 1.49 | 7 | 0.75 | 6.03 | 26.34 |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxx% | x | x | xx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxx | xxxxx | xxxxx |